Literature DB >> 23994106

Factors associated with an increased risk of recurrence in women with ovarian granulosa cell tumors.

Anuj Suri1, Ebony B Carter, Neil Horowitz, Sheri Denslow, Paola A Gehrig.   

Abstract

INTRODUCTION: Studies demonstrate that patient factors such as race, body composition, medical co-morbidities, and medications may be associated with cancer related outcomes independent of the patient's malignancy and related therapies for the cancer. The goal of this study is to determine demographic and prognostic factors affecting disease recurrence in women with early stage ovarian granulosa cell tumors (GCT).
MATERIALS AND METHODS: This study used a dual-institution retrospective analysis of women diagnosed with GCT between 1995 and 2010. Demographics including age, race, body mass index (BMI), stage, diabetes (DM), adjuvant treatment, and progression-free survival (PFS) were extracted. Hazard ratios for recurrence were estimated by univariate and multivariate Cox regression models.
RESULTS: One hundred and four women were identified with a median age of 50 years (range 12-87 years). Fifty-five (58.5%) were Caucasian, 29 (30.9%) African American, and 10 (10.2%) others. Median BMI was 29 kg/m(2) (range 12-57 kg/m(2)). Twenty-one patients had DM. The majority of women had clinical stage I disease (95.0%), 5 (6.4%) had stage II/III disease, and 5 were unstaged. In univariate analysis among early stage disease, DM showed the strongest association with recurrence (HR=3.37, 95% CI=1.38-8.20). In multivariate analysis, DM was associated with an HR of 3.19 for recurrence (95% CI=1.08-9.44).
CONCLUSIONS: Our results emphasize that diabetes is one of the strongest predictors of recurrent disease in patients with ovarian GCTs. As this disease is characterized by long disease-free intervals prior to recurrence, this may serve as a potential chemopreventive strategy in patients felt to be at higher risk for recurrence.
© 2013.

Entities:  

Keywords:  Diabetes; Granulosa cell tumor; Obesity; Ovary

Mesh:

Year:  2013        PMID: 23994106     DOI: 10.1016/j.ygyno.2013.08.013

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Ruptured granulosa cell tumor of the ovary presenting with catastrophic intra-abdominal hemorrhage: A case report.

Authors:  Alexa D Smith; Mojdeh S Kappus; Wilfrido D Mojica; Martin J Caliendo; Connor Foote; Peter Muscarella
Journal:  Int J Surg Case Rep       Date:  2022-06-15

2.  A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study.

Authors:  Elizabeth R Burton; Mark Brady; Howard D Homesley; Peter G Rose; Toshiaki Nakamura; Joshua P Kesterson; Jacob Rotmensch; J Tate Thigpen; Linda Van Le
Journal:  Gynecol Oncol       Date:  2015-11-23       Impact factor: 5.482

3.  Inhibition of STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian cancer cells.

Authors:  Li-Xia Zhong; Hong Li; Mo-Li Wu; Xiao-Yu Liu; Ming-Jun Zhong; Xiao-Yan Chen; Jia Liu; Yang Zhang
Journal:  J Ovarian Res       Date:  2015-04-22       Impact factor: 4.234

4.  Association between diabetes mellitus and progression free survival in women with ovarian granulosa cell tumors.

Authors:  Joan R Tymon-Rosario; Eirwen M Miller; Gregory M Gressel; Nicole S Nevadunsky
Journal:  Gynecol Oncol Rep       Date:  2018-10-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.